Provided by Tiger Trade Technology Pte. Ltd.

Eupraxia Pharmaceuticals

8.50
+0.38004.68%
Post-market: 8.500.00000.00%16:04 EST
Volume:608.88K
Turnover:5.18M
Market Cap:430.51M
PE:-9.66
High:8.79
Open:8.13
Low:8.13
Close:8.12
52wk High:9.32
52wk Low:2.68
Shares:50.65M
Float Shares:39.63M
Volume Ratio:1.66
T/O Rate:1.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8798
EPS(LYR):-0.7642
ROE:-61.02%
ROA:-36.21%
PB:7.38
PE(LYR):-11.12

Loading ...

Eupraxia Pharmaceuticals Closes $63.2 Million Offering

MT Newswires Live
·
34 mins ago

Eupraxia Pharmaceuticals Launches Cross-Border Equity and Warrant Offering Under New Underwriting Pact

TIPRANKS
·
Yesterday

Eupraxia Pharmaceuticals Prices $55 Million Public Offering

MT Newswires Live
·
Yesterday

Eupraxia Pharmaceuticals 6.4M share Spot Secondary priced at $7.00

TIPRANKS
·
Feb 19

Eupraxia Pharmaceuticals announces common shares offering, no amount given

TIPRANKS
·
Feb 19

Eupraxia Pharmaceuticals Announces Proposed Public Offering

GlobeNewswire
·
Feb 19

Eupraxia Pharmaceuticals management to meet with Cantor

TIPRANKS
·
Feb 03

Eupraxia Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Jan 15

Eupraxia Pharmaceuticals price target raised to $19 from $11 at Cantor Fitzgerald

TIPRANKS
·
Jan 15

H.C. Wainwright Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)

TIPRANKS
·
Jan 09

Eupraxia Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 09

Eupraxia Trial Data Shows Lasting Tissue Healing In Patients With Inflamed Esophagus

Benzinga_recent_news
·
Jan 09

Eupraxia Pharmaceuticals Up Nearly 16%, on Pace for Largest Percent Increase Since November 2024 -- Data Talk

Dow Jones
·
Nov 11, 2025

Eupraxia Pharmaceuticals Q3 EPS $(0.19) Beats $(0.21) Estimate

Benzinga
·
Nov 05, 2025

Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

GlobeNewswire
·
Nov 05, 2025

Eupraxia Pharmaceuticals Releases Q3 2025 Financial Results

TIPRANKS
·
Nov 05, 2025

Eupraxia Pharmaceuticals Advances EoE Treatment with EP-104GI Trial

TIPRANKS
·
Oct 28, 2025

Eupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion

TIPRANKS
·
Oct 01, 2025

Raymond James Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)

TIPRANKS
·
Sep 30, 2025

Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering

TIPRANKS
·
Sep 30, 2025